N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M1 receptor

Neuropharmacology

Volumn 58, Issue 8, 2010, Pages 1206-1214

  Thomas, David R ^a   Dada, Adeshola ^a   Jones, Gareth A ^a   Deisz, Rudolf A ^b   Gigout, Sylvain ^b   Langmead, Christopher J ^a   Werry, Tim D ^a   Hendry, Nicola ^a   Hagan, Jim J ^a,b   Davies, Ceri H ^a,b   Watson, Jeannette M ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antagonist; Human tissue; M1; Muscarinic; N desmethylclozapine

Indexed keywords

CARBACHOL; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MUSCARINIC M1 RECEPTOR; NORCLOZAPINE; OXOTREMORINE M; SULFUR 35; TRITIUM;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN TISSUE; HUMAN VERSUS ANIMAL COMPARISON; MALE; MEMBRANE BINDING; NERVE CELL STIMULATION; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

EID: 77952885726     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.02.017     Document Type: Article

References (39)

1. Akam E.C., Challiss R.A.J., Nahorski S.R. G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype. Br. J. Pharmacol. 2001, 132:950-958.
2. Ames R.S., Nuthulaganti P., Fornwald J.A., Shabon U., Van-der Keyl H.K., Elshourbagy N.A. Heterologous expression of G-protein coupled receptors in U-2OS osteosarcoma cells. Recept. Channels 2004, 10:117-124.
3. 1 muscarinic receptor mutant mice. Nat. Neurosci. 2003, 6:51-58.
4. Bodick N.C., Offen W.W., Levey A.I., Cutler N.R., Gauthier S.G., Satlin A., Shannon H.E., Tollefson G.D., Rasmussen K., Bymaster F.P., Hurley D.J., Potter W.Z., Paul S.M. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioural symptoms in Alzheimer disease. Arch. Neurol. 1997, 54:465-473.
5. Bymaster F.P., Felder C., Ahmed S., McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 2002, 1:163-181.
6. Connors B.W., Gutnick M.J. Intrinsic firing patterns of diverse neocortical neurons. Trends Neurosci. 1990, 13:99-104.
7. Crook J.M., Tomaskovic-Crook E., Copolov D.L., Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am. J. Psychiatry 2001, 158:918-925.
8. Dada, A., Wood, M.D., Langmead, C.J., Challiss, R.A.J., Salah-Uddin, H., Watson, J., 2007. Use of a GTPg35S immunocapture assay to measure the functional activation of muscarinic M1 receptors in rat cortex. In: British Pharmacological Society 2nd Focused Meeting on Cell Signalling P022.
9. 1 agonism a pre-requisite for mimicking clozapine's actions?. Psychopharmacology 2005, 178:451-460.
10. 1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol. Psychiatry 1996, 1:54-58.
11. Dean B., McLeod M., Keriakous D., McKenzie J., Scarr E. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 2002, 7:1083-1091.
12. 35S]guanosine-5′-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay. J. Pharmacol. Exp. Ther. 1999, 289:946-955.
13. Delmas P., Brown B.A. Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat. Rev. Neurosci. 2005, 6:850-862. (Review).
14. Dettling M., Sachse C., Brockmoller J., Schley J., Muller-Oerlinghausen Pickersgill I., Rolfs A., Schaub R.T., Schmider J. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology 2000, 152:80-86.
15. 1 muscarinic antagonist pirenzepine. Psychopharmacology 1987, 93:470-476.
16. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry 1993, 34:702-712.
17. Hasselmo M.E. The role of acetylcholine in learning and memory. Curr. Opin. Neurobiol. 2006, 16:710-715.
18. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
19. 1 receptor agonist, 77-LH-28-1. Br. J. Pharmacol. 2008, 1-12.
20. Lameh J., Burstein E.S., Taylor E., Weiner D.M., Vanover K.E., Bonhaus D.W. Pharmacology of N-desmethylclozapine. Pharmacol. Therapeut. 2007, 115:223-231.
21. Levey A.I., Kitt C.A., Simonds W.F., Price D.L., Brann M.R. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 1991, 11:3216-3226.
22. Levey A.I. Muscarinic acetylcholine receptor expression in memory circuits - implications for treatment of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:13541-13546.
23. 1 muscarinic receptors. Neuropsychopharmacology 2005, 30:1986-1995.
24. 1 muscarinic receptor potentiates N-methyl-d-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:11465-11470.
25. Mauri M.C., Volonteri L.S., Fiorentini A., Invernizzi G., Nerini T., Baldi M., Bareggi S.R. Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients. Schizophr. Res. 2004, 66:197-198.
26. McCormick D.A., Connors B.W., Lighthall J.W., Prince D.A. Comparative electrophysiology of pyramidal and sparsely spiny stellate neurons of the neocortex. J. Neurophysiol. 1985, 54:782-806.
27. Meltzer H.Y., Alphs L., Green A.I., Altamura A.C., Anand R., Bertoldi A., Bourgeois M., Chouinard G., Zahur Islam M., Kane J., Krishnan R., Lindenmayer J.P., Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 2003, 60:82-91.
28. i values. J. Pharmacol. Exp. Ther. 1989, 251:238-246.
29. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 1999, 25:233-255.
30. 1-selective ligand muscarinic toxin 7 (MT-7). Br. J. Pharmacol. 2000, 131:447-452.
31. q/11 protein coupling in membranes prepared from post mortem human brain tissue. J. Pharmacol. Exp. Ther. 2008, 325:869-874.
32. Scarr, E., Cowie, T.F., Kanellakis, S., Sundram, S., Pantelis, C., Dean, B., 2008. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol. Psychiatry. Advance online publication, 4 March 2008. doi:10.1038/sj.mp.2008.28.
33. 1 receptors. J. Pharmacol. Exp. Ther. 1994, 269:271-281.
34. Shekhar A., Potter W.Z., Lightfoot J., Lienemann J., Dube S., Mallinckrodt C., Bymaster F.P., McKinzie D.L., Felder C.C. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 2008, 165:1033-1039.
35. Sporn A.L., Vermain A., Greenstein D.K., Bobb A.J., Spencer E.P., Clasen L.S., Tossell J.W., Stayer C.C., Gochman P.A., Lenane M.C., Rapoport J.L., Gogtay N. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J. Am. Acad. Child Adolesc. Psychiatry 2007, 46:1349-1356.
36. Sur C., Mallorga P.J., Wittmann M., Jacobson M.A., Pascarella D., Williams J.B., Brandish P.E., Pettibone D.J., Scolnick E.M., Conn P.J. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:13674-13679.
37. Tsai G., Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. 2002, 42:165-179.
38. 5 muscarinic receptor distribution in rat CNS by RT-PCR and HPLC. J. Neurochem. 1994, 63:815-821.
39. 1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 2004, 177:207-216.